Published in

Taylor and Francis Group, Pediatric Hematology and Oncology, 4(38), p. 331-345, 2021

DOI: 10.1080/08880018.2020.1868637

Links

Tools

Export citation

Search in Google Scholar

Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity

Journal article published in 2021 by Yasmina Mozo, David Bueno, Luisa Sisinni, Alba Fernández-Arroyo, Blanca Rosich, Antonio Pérez Martínez ORCID, María Isabel Benítez-Carabante, Laura Alonso, María Luz Uría, Cristina Díaz de Heredia, Carmen Mestre-Duran, Cristina Ferreras Bárbara Pascual ORCID, Juan Torres, Itsaso Losantos, Adela Escudero ORCID and other authors.
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO